Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061802 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
A Phase 4 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 4
- Development phase
- 225
- Enrollment target
NCT00061802 is a Phase 4 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 225 participants.
The verdict
NCT00061802, a Phase 4 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 225 participants
- Enrollment target
Study Summary
A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder
Interventions
- DRUG risperidone, quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061802
The ClinicalTrials.gov registry entry for NCT00061802 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which risperidone, quetiapine is the first listed.
NCT00061802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061802 about?
NCT00061802 is a clinical study titled "Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder". A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder
What is the current status of trial NCT00061802?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 225 participants. The study started on 2003-06. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00061802?
The interventions under investigation include: risperidone, quetiapine (DRUG).
Who is sponsoring clinical trial NCT00061802?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.